NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO THE U.S NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
Reference is made to the stock exchange notice released earlier today by Hofseth BioCare ASA ("HBC" or "Company") regarding a private placement of NOK 23.6 million through issuance of 11,800,000 new shares (the "Private Placement"). The subscription price in the Private Placement was NOK 2 per share.
In the Private Placement, the following subscribers surpassed a threshold for disclosure of large shareholdings:
- Bonafide Global Fish Fund subscribed 2,000,000 new shares and thus increased their total shareholding in the Company to 5.64 %. Following the Private Placement, Bonafide Global Fish Fund owns 6,892,203 shares in the Company.
- Hofseth AS subscribed 5,302,571 new shares and thus increased their total shareholding in the Company to 10.4 %. Following the Private Placement, Hofseth AS owns 12,713,514 shares in the Company.
- Hofseth International AS subscribed 1,750,000 new shares and thus increased their total shareholding in the Company to 3,46 %. Following the Private Placement, Hofseth International AS owns 6.87 % in the Company including related companies, Hofseth Logistics AS and Seafood Farmers of Norway AS. Hofseth International AS (and associated companies) holds a total shareholding of 8,397,881 shares in the Company.
- As a consequence of the Private Placement, the shareholding of Jan Petterson (and associated companies) in the Company has decreased to 9.2%. Following the Private Placement, Jan Pettersson (and associated companies) still own 11,245,651 shares in the Company.
For more information, please contact:
Jon Olav Ødegård, CEO Hofseth BioCare ASA
Mobile: +47 936 32 966
About Hofseth BioCare ASA:
HBC is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. HBC's objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.